



Europäisches Patentamt

European Patent Office

Office européen des brevets

Publication number:

0 088 695
A2

12

EUROPEAN PATENT APPLICATION

21 Application number: 83400461.6

51 Int. Cl.³: G 01 N 33/54

22 Date of filing: 07.03.83

30 Priority: 09.03.82 US 356315
16.11.82 US 442050

43 Date of publication of application: 14.09.83
Bulletin 83/37

84 Designated Contracting States: BE CH DE FR GB IT LI
LU NL SE

71 Applicant: CYTOGEN CORPORATION, 201 College Road
East Forrester Research Center, Princeton New
Jersey 08540 (US)

72 Inventor: McKearn, Thomas Joseph, RD1, Box 22-4, New
Hope Pennsylvania 18938 (US)
Inventor: Goers, John Walter Frank, 38 Sayre Drive,
Princeton New Jersey 08540 (US)
Inventor: Rodwell, John Dennis, 430 Ramsey Road,
Yardley Pennsylvania 19067 (US)
Inventor: Lee, Chyi, 1347 Ute Road, North Brunswick
New Jersey 08902 (US)

74 Representative: Warcoln, Jacques et al, Cabinet
Régimbeau 26, avenue Kléber, F-75116 Paris (FR)

54 Antibody conjugates.

57 Methods for covalently attaching soluble or insoluble conjugate partners (compounds, linkers or supports) to antibody molecules to form antibody conjugates useful in affinity purification, separation, diagnostic and therapeutic applications. Conjugate partners are attached to (a) carbohydrate moieties of antibody molecules, (b) sulfhydryl groups of antibody molecules or (c) amino or carboxy groups of the F_c region of antibody molecules to provide antibody conjugates which substantially retain the immunospecificity and immunoreactivity of the antibodies from which they are made. A method is described for the covalent attachment of linker groups via amide or ester bonds to compounds which contain available amino or hydroxy groups. The linkers may be designed so that they are susceptible to cleavage by any one of the serum complement enzymes.

EP 0 088 695 A2

ANTIBODY CONJUGATES

TABLE OF CONTENTS

5			<u>Page</u>
	1.	Field of the Invention.....	3
	2.	Background of the Invention.....	4
10	2.1.	Covalent Attachment.....	4
	2.2.	Non-Covalent Attachment.....	6
	2.3.	Carrier Systems.....	7
	3.	Summary of the Invention.....	11
15	4.	Brief Description of Figures.....	14
	5.	Detailed Description of the Invention.....	16
	5.1	Choice of Antibody.....	16
	5.2	Methods for Attaching Compounds to Antibody Molecules.....	19
20	5.2.1.	Attachment to the Carbohydrate Moiety of the Antibody.....	19
	5.2.1.1.	Chemical Methods of Oxidation.....	20
25	5.2.1.2.	Enzymatic Methods of Oxidation.....	21
	5.2.1.3.	Preparation of Antibody Conjugates.....	21
30	5.2.1.4.	Stabilization of the Antibody Conjugates.....	22

		<u>Page</u>
	5.2.2. Attachment to Sulfhydryl Groups of the Antibody Molecule.....	22
5	5.2.3. Attachment to Amino or Carboxy Groups of the Fc Region of the Antibody Molecule.....	25
	5.3. Conjugate Partners.....	27
	5.3.1. Compounds of Interest.....	28
	5.3.2. Soluble Linkers.....	29
10	5.3.3. Insoluble Supports.....	29
	5.4. Carrier Systems.....	30
	5.5. Serum Complement and Selection of Linkers...	32
15	5.6. Additional Uses of Antibody Conjugates.....	44
	6. Examples: Series I.....	45
	6.1. Oxidation of the Carbohydrate Moiety of the Antibody Molecule.....	45
20	6.2. Preparation of the Tripeptide-AMC for Attachment to the Antibody Molecule.....	46
	6.3. Covalent Attachment of Phenylhydrazide- Tripeptide-AMC to the Oxidized Carbohydrate Moiety of the Antibody Molecule.....	48
	7. Examples: Series II.....	49
25	7.1. Oxidation of Mouse Monoclonal IgM.....	50
	7.2. Attachment of Linker to EDDHA.....	50
	7.3. Preparation of IgM-Linker-EDDHA Conjugates..	51
30	7.4. Carbodiimide Attachment of Linker-EDDHA to IgM.....	52
	7.5. Carbodiimide Attachment of EDDHA to IgM.....	53
	7.6. Effects of Carbohydrate-Mediated Attachment of Antibodies.....	53
35		

	<u>Page</u>
8. Examples: Series III.....	55
8.1. Antibody Attachment to Aminohexyl-Sepharose.....	55
5 8.2. Separations.....	56
9. Examples: Series IV.....	58
9.1. Complement Fixation Assays.....	60
9.1.1. Preparation of Human Complement.....	60
10 9.1.2. Hemolytic Assay for Complement Fixation.....	60
9.1.3. Non-Hemolytic Assay for Complement Mediated Release of AMC.....	61
15	

1. FIELD OF THE INVENTION

20 The present invention relates to the covalent
attachment of antibodies, including monoclonal antibodies
and polyclonal antibodies (conventional antisera), to
soluble or insoluble conjugate partners (compounds,
linkers or supports) to form antibody conjugates which are
25 useful in a variety of affinity purification, separation,
diagnostic and therapeutic applications.

 More particularly, the invention is directed to
methods of attachment to the carbohydrate moieties of an
30 antibody molecule located outside the antigen binding
domain of the antibody molecule, to sulfhydryl groups of
the antibody molecule, and to the amino or carboxy groups
of the F_C region of antibodies. The product conjugates
substantially retain the entire immunospecificity and
35 immunoreactivity of the antibodies from which they are

made, and further retain the ability to activate complement.

5 This invention also relates to the general area of carrier systems capable of delivering compounds to target sites in vivo or in vitro. Such systems include the general area of the delivery of pharmaceutical agents or other compounds to target sites in vivo, both in vitro and in vivo imaging systems (e.g., tumor imaging systems),
10 cell sorting systems and separation schemes based upon antigen-antibody interactions.

The present invention also includes the
- attachment of a substrate-linker to an antibody so that
15 the resulting antibody conjugates retain the ability to bind antigen and activate complement. In selected applications, this promotes the release of the compound in its active form at the target site.

20 2. BACKGROUND OF THE INVENTION

2.1. COVALENT ATTACHMENT

Various reactions can be used to covalently
25 attach compounds to antibodies. This has been accomplished by reaction of the amino acid residues of the antibody molecule, including the amine groups of lysine, the free carboxylic acid groups of glutamic and aspartic acid, the sulfhydryl groups of cysteine and the various
30 moieties of the aromatic amino acids.

There are serious disadvantages to these methods of covalent attachment to the polypeptide backbone of an antibody molecule. The amino acid sequences of the light
35 and heavy chains of immunoglobulins contain all of the

amino acids relatively regularly and randomly dispersed throughout the molecule, including the antigen binding region. To the extent any chemical modification occurs in this antigen binding region, one has introduced a change
5 in the recognition element of the antibody. Such changes would be expected to, and, in fact do, change the affinity and specificity of the antibody for antigen. In a population of different antibodies, such alteration in the antigen binding region results in complete inactivation of
10 some antibodies and in lesser degrees of inactivation of others in relation to the proximity of the alteration to the antigen binding site. This inactivation may be due to a change within the antigen binding site to change the conformation of the binding site so as to make it
15 unreactive, or may be due to a change in a region outside the antigen binding region so as to limit access of antigen to the antigen binding region.

Probably the most commonly used non-specific
20 method of covalent attachment is the carbodiimide reaction to link carboxy groups of a compound to amino groups of the antibody. Additionally, bifunctional agents such as dialdehydes or imidoesters have been used to link the amino group of a compound to amino groups of the antibody
25 molecule. Some investigators have used the Schiff base reaction to link compounds to antibody molecules. This method involves the periodate oxidation of a drug or cytotoxic agent that contains a glycol or hydroxy group, thus forming an aldehyde which is then reacted with the
30 antibody molecule. Attachment occurs via formation of a Schiff base with amino groups of the antibody molecule. Additionally, compounds with reactive sulfhydryl groups have been coupled to antibody molecules. Isothiocyanate can be used as a coupling agent for covalently attaching
35 compounds to antibodies. This method has been used to

attach fluorescent compounds to antibody molecules for use in fluorescence microscopy (Brandtzaeg, 1973, Scand. J. Immunol. 2:273-290) and cell sorting systems (Loken and Herzenberg, 1975, Annals N.Y. Acad. Sci. 254:163-171).

5

Interchain disulfide bonds can also be used as sites of covalent attachment. If one is successful in selectively reducing only the interchain disulfide bonds, several functional properties of the antibody may be adversely affected, such as functional affinity, agglutination ability and the ability to fix complement.

10

2.2. NON-COVALENT ATTACHMENT

Alternative methods of attachment to antibody molecules outside the antigen binding region (outside the variable domains) may involve use of antibodies directed against the constant domain of the antibody molecule, or use of Staphylococcal protein A which is known to bind specifically to a site on the constant region. Since these modes of attachment are non-covalent, either approach is limited and would not be efficient for separation and purification schemes. Any dissociation of antigen would likely lead to release of antibody from the support to which it is non-covalently attached, so selective elution of antigen cannot be accomplished. Additionally, with respect to carrier systems (see Section 2.3), since non-covalent bonds are more likely to be broken before the antibody complex reaches the target site, covalent linkages are preferred.

25

30

2.3 CARRIER SYSTEMS

A number of agents have been utilized as carrier molecules with limited success in drug delivery systems.

35

In practice the carrier should be non-toxic and target site specific. Ideally there should be a mechanism for release of the active form of the compound from the carrier at the target site. Carrier molecules such as DNA, liposomes, proteins, steroid hormones, and antibodies (whole antibody molecules or Fab fragments) have been used in conjunction with a broad spectrum of pharmaceutical or cytotoxic agents such as: radioactive compounds (e.g., I^{125} , I^{131}); agents which bind DNA, for instance, alkylating agents or various antibiotics (e.g., daunomycin, adriamycin, chlorambucil); antimetabolites such as methotrexate; agents which act on cell surfaces (e.g., venom phospholipases and microbial toxins); and protein synthesis inhibitors (e.g., diphtheria toxin and toxic plant proteins). For reviews on the subject see Bale et al., 1980, Cancer Research 40:2965-2972; Ghose and Blair, 1978, J. Natl. Cancer Inst. 61(3):657-676; Gregoriadis, 1977, Nature 265:407-411; Gregoriadis, 1980, Pharmac. Ther. 10:103-118; Trouet et al., 1980, Recent Results Cancer Res. 75:229-235. Some of the delivery systems which are more pertinent to the present invention are discussed below.

Liposome mediated delivery of pharmaceutical agents has major drawbacks because of its lack of target specificity. Recently, investigators have attempted to overcome this problem by covalently attaching whole antibody or Fab fragments to liposomes containing a pharmaceutical agent (Heath et al., 1981, Biochim. Biophys. Acta 640:66-81; Huang et al., 1980, J. Biol. Chem. 255(17):8015-8018; Jansons and Mallet, 1981, Anal. Biochem. 111:54-59, Martin et al., 1981, Biochem. 20:4229-4238). Others have reported the coupling of protein A (Staph A protein) to liposomes in order to direct the preparation to multiple specific targets which

have previously been bound to antibodies. Such targets are simply limited by the antibodies used (Leserman et al., 1980, Nature 288:602-604). However, an intrinsic problem of particular importance in any liposome carrier system is that in most cases the targeted liposome does not selectively reach its target site in vivo. Whether or not liposomes are coated with antibody molecules, liposomes are readily phagocytosed by macrophages and removed from circulation before reaching other target sites.

Most investigators have recognized another major problem inherent in the liposome targeting system, which is that binding of the targeted liposomes to the target cell does not ensure incorporation of the liposome contents, hence, the pharmaceutical agent, into the target cell (Weinstein et al., 1978, Biochim. Biophys. Acta 509:272-288). A few investigators have tried to overcome this problem by targeting liposomes using receptor specific compounds which would be internalized into the target cell (Leserman et al., 1980, Proc. Natl. Acad. Sci., U.S.A. 77(7):4089-4093; Mauk et al., 1980, Proc. Natl. Acad. Sci., U.S.A. 77(8): 4430-4434). The problem of internalizing the liposome contents still exists, however, because not all tumor cells are actively phagocytic. For instance, fibrosarcoma cells are much less phagocytic than are cells of lymphomas and leukemias. Thus, these liposome mediated delivery systems rely upon the ability of the target cell itself to internalize a substance which will be ultimately lethal to the cell.

Finally, if the liposome is internalized into the target cell, there is no assurance that the pharmaceutical agent will be released in its active form. After

phagocytosis the liposome contents are packaged within lysosomes of the target cell. The array of proteolytic enzymes contained within the lysosome may either degrade the pharmaceutical agent or render the agent inactive by
5 altering its structure or cleaving the active site. The variety of proteolytic enzymes contained in the lysosome makes it very difficult, if not impossible, to devise bonding arrangements that will allow release of the pharmaceutical agent in its active form. Thus, reliance
10 upon the enzyme content of the target cell lysosomes is, at best, a haphazard system to effect release of the active form of the pharmaceutical agent.

A number of investigators have reported target
15 systems involving attachment of compounds or pharmaceutical agents directly to conventional antibodies, monoclonal antibodies, or to Fab portions of antibodies directed against tumor antigens. See review articles, supra, and Blythman et al., 1981, Nature 290:145-146;
20 Davis and Preston, 1981, Science 213:1385-1388; Hurwitz et al., 1979, Int. J. Cancer 24:461-470; U.S. Patent No. 4,093,607; and U.K. Patent No. 1446536. Urdal and Hakomori (1980, J. Biol. Chem. 255(21):10509-10579) describe an antibody targeted, avidin mediated, drug
25 killing of tumor cells.

Various investigators have examined proteins other than antibodies as carriers in a target system. For example, desialylated glycoproteins are preferentially
30 taken up by hepatocytes. See review articles, supra, and Bernstein et al., 1978, J. Natl. Cancer Inst. 60(2):379-384.

Although antibody carrier systems are more
35 specific for the target than are the liposome carrier

systems, a significant problem exists in the release of the pharmaceutical agent at the target site. As in the liposome mediated systems, the antibody-drug compounds must be internalized by the tumor cell so that the drug
5 can be released through cleavage by lysosomal enzymes (see review articles, supra). Additionally, the nonspecific linkage of the pharmaceutical agent to random sites on the antibody molecule may interfere with antigen binding capacity, thus reducing the effectiveness of the system.

10

Radiopharmaceutical techniques currently used in non-invasive in vivo imaging methods are based upon the ability of the target organ to remove the radiopharmaceutical label from the circulation. These techniques
15 utilize various substances to deliver radioactive compounds to desired targets; such substances include substrates, substrate analogs, ligands, hormones, radionuclides, bifunctional chelates (linker groups containing a chelator at one end which is able to bind a
20 heavy metal or radionuclide and a reactive group at the other end which can covalently attach to a target cell) and liposomes (Spencer, R.P., ed. 1980. Radiopharmaceuticals Structure-Activity Relationship. Grune & Stratton, New York; Eckelman and Levanson, 1977, Intl. J.
25 Appl. Radiation and Isotopes 28:67-82). Other non-invasive techniques currently available are emission tomography, nuclear magnetic resonance imaging, and in vivo spectroscopy. See review article by Brownell et al., 1982, Science 215:619-626 where the authors suggest the
30 application of labeled antibodies in the field of radiopharmaceuticals.

35

3. SUMMARY OF THE INVENTION

The present invention relates to the covalent attachment of compounds to antibody molecules so that the
5 resulting antibody conjugates retain the ability to bind antigen and activate complement. In particular, such methods of attachment include attachment to the carbohydrate moieties of antibodies, the sulfhydryl groups of antibodies and the amino or carboxy groups of the F_c
10 region of antibodies.

In a preferred embodiment, the present invention is concerned with covalent attachment to the carbohydrate moieties of the heavy chains of antibodies, and,
15 generally, to the CH_2 domain. Since the carbohydrate is in the constant region of the antibody (outside the variable domain), modification of the carbohydrate per se will not directly introduce reactive or interfering groups into the variable domain. Hence, such an approach is an
20 attractive means for covalent modification of antibodies without seriously adversely affecting immunoreactivity and immunospecificity.

According to the preferred embodiment, antibodies
25 are modified by covalent attachment to the carbohydrate moiety using known reagents and reactions. Instead of dealing with protein chemistry, the present applicants utilize those reactions of carbohydrate chemistry unique to carbohydrates to modify the carbohydrate of the
30 glycoproteins. In principle, there are many different enzymatic and non-enzymatic reactions that are directed primarily, if not exclusively, to carbohydrate moieties.

The product conjugates of the present invention
35 have been found to retain substantial, if not complete,

immunoreactivity and immunospecificity. When such conjugates are prepared using monoclonal antibodies, the association constant and index of heterogeneity are unaffected by the present mode of covalent modification, 5 whereas conventional means of modification decrease the average binding constant and introduce functional heterogeneity. Furthermore, the reagents usable with the novel techniques of the invention can be extremely selective so that there is no detectable reaction of the 10 polypeptide portion of the antibody molecule. This procedure can be performed on intact molecules or functional monovalent fragments of antibodies. Finally, the modification can be done with a variety of antibody classes, including IgA, IgD, IgE, IgG and IgM, and 15 antibodies from any source, including monoclonal antibodies.

This invention also encompasses the use of antibodies as carrier molecules for the targeting of a 20 compound or compounds for delivery to specific cells, tissues, organs, or any other site in vivo, or in vitro and the subsequent complement-mediated release of the compound at the target site. Alternatively, release may be mediated by serum proteases.

25 Antibodies directed against any desired target (e.g., antigenic determinants of tumor cells, virus, fungi bacteria, or parasites) may be used as carrier molecules. Although conventional antibodies may be used as carrier 30 molecules, monoclonal antibodies offer the advantages of increased specificity for antigen, improved efficiency of the delivery system and ease in production.

Once administered in vivo, the carrier antibody 35 molecule will attach to the antigenic determinant of the

target site. The subsequent release of the linked compound is dependent upon complement activation or serum proteases. Complement is the collective name for a group of serum proteins which are sequentially activated (the complement cascade) by the formation of certain immune complexes. Several of the complement components of the cascade have proteolytic activity which is specific for particular substrates or chemical bonds.

According to one process of the present invention, a compound is attached to an antibody carrier molecule of an immunoglobulin class that is capable of complement activation. This attachment is accomplished via linkers which are susceptible to cleavage by one or more of the activated complement enzymes, and one or more different compounds may be attached to each antibody molecule. The resulting antibody conjugate is administered to an individual. Subsequent to the binding of the modified antibody and antigen in vivo, the individual's serum complement is activated and the compounds will be selectively cleaved and released at the target site. Such conjugates may also be used for the in vitro detection and identification of target antigen in a complement-fixation assay system.

For the practice of this invention it is desirable to attach the compound to the antibody molecule without interfering with either the antigen binding capacity of the antibody, or with the ability to activate complement (also called complement fixation). The present invention describes the novel linkers and methods of attachment which may be used to attach compounds to any antibody capable of activating complement.

Alternatively, certain techniques, such as tumor imaging, or separation schemes based upon antigen-antibody interactions, wherein the antibodies are attached to an insoluble matrix, require that the compound remain
5 attached to the target site. In an alternate embodiment, when cleavage at the target site is not desirable, then the linker group utilized is insensitive to the activated complement proteins, or the antibody molecule is of a class or type that does not activate complement.

10 Finally, for delivery of other compounds, e.g., hormones or neurotransmitters, where it may be desirable to cleave the compound without activation of the complement cascade, one may use a serum protease sensitive
15 linker attached to an antibody that does not fix complement.

4. BRIEF DESCRIPTION OF FIGURES

20 The present invention may be more fully understood by reference to the following detailed description of the invention, examples of specific embodiments of the invention and the appended figures in which:

25 FIG. 1 is a schematic representation of an antibody molecule or immunoglobulin of the IgG class (a), and of the IgM class (b).

30 FIG. 2 represents a portion of the complement cascade activated by the classical pathway. C1 through C9 represent complement proteins. The bar over certain numbers indicates an active enzyme. S' represents a site on the cell membrane.

35

FIG. 3 depicts a general reaction scheme for the attachment of the antineoplastic drug, Alkeran (Burroughs-Wellcome), to the peptide CBZ-gly-gly-arg.

5 FIG. 4 represents the excitation spectra for (a) unoxidized antibody and (b) antibody oxidized in accordance with Section 6.1.

10 FIG. 5 represents the excitation and emission spectra of the Phenylhydrazine-Tripeptide-AMC compound prepared in accordance with Section 6.2.

15 FIG. 6 represents the excitation and emission spectra of the Antibody-Phenylhydrazine-Tripeptide-AMC (APTA) conjugate prepared in accordance with Section 6.3.

20 FIG. 7 represents Sips plots of fluorescent quenching data using unmodified antibody (●-●); antibody modified by the method of the invention (Δ-Δ); and antibody modified by attachment (carbodiimide) to aspartic and/or glutamic amino acids (■-■).

25 FIG. 8 represents the results of experiments showing the specific complement mediated release of AMC along with certain controls. Fluorescence is monitored at 460 nm with excitation at 380 nm. An increase in fluorescence indicates release of AMC from the Antibody-Phenylhydrazine-Tripeptide-AMC (APTA) conjugate; (a) represents APTA conjugate incubated with
30 glutaraldehyde-fixed sheep red blood cells and human complement; (b) represents APTA conjugate incubated with glutaraldehyde-fixed rat red blood cells and human complement; (c) represents APTA conjugate incubated with glutaraldehyde-fixed sheep red blood cells; (d) represents
35 APTA conjugate alone.

5. DETAILED DESCRIPTION OF THE INVENTION

Glycoproteins are one of the several types of biologically important macromolecules which have found application in selected therapeutic and/or diagnostic settings. Although the currently recognized classes of glycoproteins are far from complete, a catalog of such materials would include immunoglobulins, serum complement components, a variety of enzymes, cell surface histocompatibility antigens and cell surface receptors. These compounds have carbohydrate residues which are covalently attached to a polypeptide backbone. Antibodies are one class of glycoproteins whose carbohydrate moieties are generally located on the heavy chain of the immunoglobulin molecule. (See FIG. 1 for a schematic representation of several immunoglobulins.) The Fab or Fab' fragments of any immunoglobulins which contain carbohydrate moieties may also be utilized in the reaction scheme described herein. The Fab' fragments of IgG immunoglobulins are obtained by cleaving the antibody molecule with pepsin [resulting in a bivalent fragment, (Fab')₂] or with papain (resulting in two univalent fragments, 2 Fab).

25 5.1. CHOICE OF ANTIBODY

According to the present invention, antibodies directed against any antigen or hapten may be used. Although conventional antibodies (antisera) may be used, monoclonal antibodies offer several advantages. Each monoclonal antibody is specific for one antigenic determinant. In addition, unlimited amounts of each monoclonal antibody can be produced. Antibodies used in the present invention may be directed against any determinant, e.g., tumor, bacterial, fungal, viral,

parasitic, mycoplasmal, histocompatibility, differentiation and other cell membrane antigens, pathogen surface antigens, toxins, enzymes, allergens, drugs and any biologically active molecules.

5

Drugs of particular interest are opioids, amphetamines, barbiturates, steroids, catecholamines, dilantin, theophylline, histamine, cannabinoids, and the like. For a more complete list of antigens, see U.S. Patent 4,193,983, particularly columns 7-11, which patent specification is incorporated herein by reference.

10

When delivery and release of the compound attached to the antibody are desired, immunoglobulins of the IgM class or certain subclasses of IgG should be used since these are the types of immunoglobulin that are known to activate complement. In other applications carrier immunoglobulins may be used which are not capable of complement activation. Such immunoglobulin carriers may include: certain classes of antibodies such as IgA, IgD, IgE; certain subclasses of IgG; or certain fragments of immunoglobulins, e.g., half antibody molecules (a single heavy:light chain pair), or Fab, Fab', or (Fab')₂ fragments. When imaging of in vivo targets is to be accomplished, the use of antibody fragments as carriers is advantageous since these fragments permeate target sites at an increased rate. Additionally, a combination of antibodies reactive to different antigenic determinants may be used.

15

20

25

30

35

TABLE I

DRUGS FOR ANTIBODY-MEDIATED DELIVERY

<u>TYPE</u>	<u>NAME/CLASS</u>	<u>LINKAGE</u>	<u>MANUFACTURER(S)</u>
Antibacterials	Aminoglycosides		
	Streptomycin	ester/amide	
	Neomycin	ester/amide	Dow, Lilly, Dome, Pfipharmics
	Kanamycin	ester/amide	Bristol
	Amikacin	ester	Bristol
	Gentamicin	ester/amide	Upjohn, Wyeth, Schering
	Tobramycin	ester/amide	Lilly
	Streptomycin B	ester/amide	Squibb
	Spectinomycin	ester	Upjohn
	Ampicillin	amide	Squibb, Parke-Davis, Comer, Wyeth, Upjohn, Bristol, SKF
	Sulfanilamide	amide	Merrell-National
	Polymyxin	amide	Burroughs-Wellcome, Dow, Parke-Davis
	Chloramphenicol	ester	Parke-Davis
Antivirals	Acyclovir		Burroughs-Wellcome
	Vira A	ester/amide	Parke-Davis
	Symmetrel	amide	Endo
Antifungals	Nystatin	ester	Squibb, Primo, Lederle, Pfizer, Holland-Rantos
Antineoplastics	Adriamycin	ester/amide	Adria
	Cerubidine	ester/amide	Ives
	Bleomycin	ester/amide	Bristol
	Alkeran	amide	Burroughs-Wellcome
	Valban	ester	Lilly
	Oncovin	ester	Lilly
	Fluorouracil	ester	Adria, Roche, Herbert
Radiopharmaceuticals	¹²⁵ I		
	¹³¹ I		
	^{99m} Tc (Technetium)		
	¹¹¹ In		
Heavy Metals	Barium		
	Gold		
	Platinum		
Antimycoplasmals	Tylosine		
	Spectinomycin		

5.2. METHODS FOR ATTACHING COMPOUNDS
TO ANTIBODY MOLECULES

In addition to the utilization of conventional
5 methods, the present invention includes several novel
methods for attaching compounds to antibody molecules:
(1) attachment to the carbohydrate moieties of the
antibody molecule, (2) attachment to sulfhydryl groups of
the antibody molecule, and (3) attachment to amino or
10 carboxy groups of the F_c region of the antibody
molecule. Whichever method is used, the attachment must
not significantly change the essential characteristics of
the antibody, such as immunospecificity and
immunoreactivity. Additional considerations include
15 simplicity of reaction and stability of the antibody
conjugate produced.

5.2.1. ATTACHMENT TO THE CARBOHYDRATE
MOIETY OF THE ANTIBODY

20 As explained in detail below, the carbohydrate
side chains of antibodies may be selectively oxidized to
generate aldehydes. The resulting aldehydes may then be
reacted with amine groups (e.g., ammonia derivatives such
25 as hydroxylamine, hydrazine, phenylhydrazine, or
semicarbazide) to form a Schiff base (e.g.; oxime,
hydrazone, phenylhydrazone or semicarbazone, respectively).

Alternatively, the carbohydrate moiety of the
30 antibody may be modified by enzymatic techniques so as to
enable attachment to or reaction with other chemical
groups. One example of such an enzyme is galactose
oxidase which oxidizes galactose in the presence of oxygen.

5.2.1.1. CHEMICAL METHODS OF OXIDATION

5 Oxidation of the carbohydrate portion or moiety
of antibody molecules leads to formation of aldehyde
groups. A variety of oxidizing agents can be used, such
as periodic acid, paraperiodic acid, sodium metaperiodate
and potassium metaperiodate. Among these, oxygen acids and
10 salts thereof are preferred since secondary or undesirable
side reactions are less frequent. For a general
discussion, see Jackson, 1944, Organic Reactions 2, p.
341; Bunton, 1965, Oxidation in Organic Chemistry, Vol. 1
(Wiberg, ed.), Academic Press, New York, p. 367.

15 Oxidation of antibodies with these oxidizing
agents can be carried out by known methods. In the
oxidation, the antibody is used generally in the form of
an aqueous solution, the concentration being generally
less than 100 mg/ml, preferably 1 to 20 mg/ml. When an
20 oxygen acid or a salt thereof is used as the oxidizing
agent, it is used generally in the form of an aqueous
solution, and the concentration is generally 0.001 to 10mM
and preferably 1.0 to 50mM. The amount of the oxygen acid
or salt thereof depends on the kind of antibody, but
25 generally it is used in excess, for example, twice to ten
times as much as the amount of the oxidizable
carbohydrate. The optimal amount, however, can be
determined by routine experimentation.

30 In the process for oxidizing antibodies with
oxygen acids or salts thereof, the optional ranges include
a pH of from about 4 to 8, a temperature of from 0° to
37°C, and a reaction period of from about 15 minutes to 12
hours.

During the oxidation of the glycoprotein with an oxygen acid or a salt thereof, light is preferably excluded to prevent over oxidation of the glycoprotein.

5

5.2.1.2. ENZYMATIC METHODS OF OXIDATION

Oxidation of the carbohydrate portion of antibody molecules may also be done with the enzyme, galactose oxidase [Cooper, et al., 1959, J. Biol. Chem. 234:445-448]. The antibody is used in aqueous solution, the concentration being generally 0.5-20 mg/ml. The enzyme generally is used at about 5-100 units per ml of solution, at a pH ranging from about 5.5 to about 8.0. The influence of pH, substrate concentration, buffers and buffer concentrations on enzyme reaction are reported in Cooper, et al., supra.

5.2.1.3. PREPARATION OF ANTIBODY CONJUGATES

The antibody conjugates of the invention may be produced by reacting the oxidized antibody with any suitable conjugate partner having an available amine group. The immediately resulting products (antibody conjugates) contain a carbon-nitrogen double bond resulting from elimination of a molecule of water from the initial addition products:




For a general discussion of the reaction of aldehydes with hydrazides, see March, 1978, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, McGraw-Hill Co., New York, p. 674.

A solution of the oxidized antibody at a concentration of from about 0.5 to 20 mg/ml is mixed with

the conjugate partner (molar ratios of reactive conjugate partner group to antibody aldehyde ranging from about 1 to about 10,000) and the solution incubated for from about 1 to 18 hours. Suitable temperatures are from 0 to 37°C and pH may be from about 6 to 8.

5.2.1.4. STABILIZATION OF THE ANTIBODY CONJUGATES

After the antibody conjugates have been formed between the antibody and its conjugate partner as described in Section 5.2.1.3, the antibody conjugates can optionally be stabilized with a suitable reducing agent, such as sodium cyanoborohydride or sodium borohydride:



Reducing agent is generally added to a molar excess of from about 10 to 100 fold molar excess over available aldehyde groups. For a general discussion, see Jentoft and Dearborn, 1979, J. Biol. Chem. 254:4359.

5.2.2. ATTACHMENT TO SULFHYDRYL GROUPS OF THE ANTIBODY MOLECULE

Free sulfhydryl groups can be generated from the disulfide bonds of the immunoglobulin molecule. This is accomplished by mild reduction of the antibody molecule. The disulfide bonds of IgG which are generally most susceptible to reduction are those that link the two heavy chains. The disulfide bonds located near the antigen binding region of the antibody molecule remain relatively unaffected (see FIG. 1). Such reduction results in the loss of ability to fix complement but does not interfere with antibody-antigen binding ability (Karush *et al.*, 1979, Biochem. 18:2226-2232). The free sulfhydryl groups generated in the intra-heavy chain region can then react


with iodoalkyl derivatives of any compound containing
carboxy or amino groups (e.g., iodoalkyl derivatives of
linker groups which are attached to a compound) to form a
covalent linkage. Such linkage does not interfere with
5 the antigen binding site of the immunoglobulin.

Antibody conjugates which are produced by
attaching a compound to free sulfhydryl groups of reduced
immunoglobulin or reduced antibody fragments do not
10 activate complement. Thus, these conjugates may be used
for in vitro separation or in vivo imaging systems where
cleavage and release of the compound is not desirable.
Such conjugates may also be used when non-complement
mediated release is desired. In such an embodiment, the
15 compound may be linked to sulfhydryl groups on the reduced
immunoglobulin, or reduced antibody fragments via linkers
which are susceptible to cleavage by serum proteases.

The Fab' fragments of IgG immunoglobulins are
20 obtained by cleaving the antibody molecule with pepsin
(resulting in a bivalent fragment, (Fab')₂) or with
papain (resulting in 2 univalent fragments, 2 Fab); see
FIG. 1. The Fab and (Fab')₂ fragments are smaller than
a whole antibody molecule and, therefore, permeate the
25 target site or tissue more easily. This offers a distinct
advantage for in vivo imaging since conjugates will more
readily penetrate in vivo sites (e.g., tumor masses,
infection sites, etc.). An additional advantage is
obtained when using conjugates formed with antibody
30 fragments because these fragments do not cross a placental
barrier. As a result, using this embodiment of the
invention, an in vivo site (such as a tumor) may be imaged
in a pregnant female without exposing the fetus to the
imaging compound.


Although attachment of a compound to sulfhydryl groups of the antibody molecule destroys complement fixation ability, such methods of attachment may be used to make antibody conjugates for use in the complement mediated release system. In such an embodiment, a compound joined to a complement sensitive substrate linker can be attached to sulfhydryls of reduced Ig molecules or antibody fragments and delivered to the target in a mixture with intact antibody molecules that are capable of activating complement. The latter would activate complement which would cleave the compound from the former. The use of antibody fragments as carrier molecules in the complement mediated release system would permit the treatment of pregnant females, and offers the advantage of more rapid penetration of the conjugate into target sites.

According to the present invention, for attachment to sulfhydryl groups of reduced antibody molecules, the substrate linkers are modified by attaching an iodoalkyl group to one end of the linker. The unmodified site on the linker may or may not be covalently attached to a compound. For instance, the substrate linkers which are ester or amide linked to compounds as prepared in Section 5.5 (see Table II and Table III) are modified by the addition of an iodoalkyl group thus forming an iodoalkyl derivatives as depicted below (N.B. the symbol * signifies an amide or ester bond):



As mentioned previously the linker may be one that is susceptible or resistant to cleavage by activated complement, or serum proteases.


When the iodoalkyl derivatives of the linker group are reacted with reduced antibody molecules or reduced antibody fragments, the linker group becomes covalently attached to the antibody molecules or
 5 fragment. This is depicted below (N.B. the symbol * signifies an amide or ester bond):



5.2.3. ATTACHMENT TO AMINO OR CARBOXY GROUPS
OF THE Fc REGION OF THE ANTIBODY MOLECULE

A modification of conventional methods for
 15 linking compounds to antibody molecules may also be used for the purposes of the present invention. These conventional methods attach compounds to amino or carboxy groups of the antibody molecule. A disadvantage of conventional methods is a decreased binding affinity of
 20 the antibody molecule for antigen (i.e., a decreased immunospecific activity) because of non-specific binding of the linkers or compounds to the Fab region (antigen binding arms) of the antibody molecule. Thus, in order to utilize conventional linking methods, the substrate linker
 25 should be directed to a more optimal position on the antibody molecule to allow immune complex formation and cleavage by complement. To this end, the antigen-binding arms (Fab regions) of the immunoglobulin or half-molecules are protected while either the amino or carboxy groups of
 30 the Fc region are reacted with a substrate linker, for example, via a soluble carbodiimide reaction. If the linker is covalently attached to a compound, any reactive groups in the compound which could interfere with binding to the antibody molecule should be blocked before reacting
 35 the antibody molecule with the linker. Once the antibody

conjugate is formed, the groups on the compound can be deblocked. The linker may be susceptible or resistant to cleavage by activated complement, or serum proteases. The extent of coupling can be controlled by limiting
5 reagents. For instance (N.B. the symbol * signifies an amide or ester bond):



15 Protection of the Fab arms may be accomplished in a number of ways. The Fab portion of the carrier antibody molecule may be bound to antibodies directed against the carrier Fab antigen binding arms (anti-Fab-antibodies).
Subsequent linking reactions will result in attachment of the compound to the unbound Fc portion of the carrier antibody molecules. The anti-Fab-antibody may be
20 immobilized on a column to allow ease in separation of reacted and unreacted components.

Such a conjugate may be prepared as follows (wash thoroughly with buffer after each step of the procedure):
25 attach the anti-Fab-antibody to an appropriate support matrix such as a cyanogen bromide activated Sepharose column. Load the column with carrier antibody so that all antigen-binding sites on the column are saturated. The Fab region of the carrier antibody is now bound and
30 protects the antigen combining sites on the anti-Fab-antibody. Treat the column with an amino group blocking agent (e.g., acetic anhydride, carbobenzoxy chloride, etc.) in order to block all free amino groups on the exposed portions of both the anti-Fab-antibody and the bound carrier antibody. The column is then washed with a
35 chaotropic agent (e.g., thiocyanate, perchlorate, iodide,

etc.) or a denaturing agent (e.g., urea, formol-urea, guanidine hydrochloride, etc.) which dissociates the carrier antibody from the anti-Fab-antibody without destroying the immunospecific activity of the anti-Fab-antibody (Dandliker et al., 1967, Biochemistry 6(5): 1460-1467). This treatment releases the carrier antibody molecules which are discarded, leaving the immobilized anti-Fab-antibody free to form subsequent immune complexes. The column, which now consists of immobilized anti-Fab-antibody, containing blocked amino groups in the non-antigen binding sites, is loaded with carrier antibody. After the carrier antibody binds to the anti-Fab-antibody, the conventional linkage reaction is carried out using a substrate linker attached to a compound. Since the only available amino groups are on the Fc portion of the carrier antibody this reaction results in attachment of the compound via the substrate linker to this portion of the carrier antibody. Finally, the resulting conjugate is released from the column by elution with an appropriate buffer (e.g., chaotropic agent or denaturant).

5.3. CONJUGATE PARTNERS

According to the methods of the invention, antibodies can be attached to any suitable conjugate partner. The major limiting factor is that the attachment reaction must (1) be selective enough to limit competing, undesirable reactions and (2) be sufficiently mild so as not to severely interfere with antibody reactivity and selectivity. For purposes of description, conjugate partners are divided into (a) compounds of interest, which are attached directly to the antibody, (b) soluble linkers, and (c) insoluble supports.

5.3.1. COMPOUNDS OF INTEREST

The conjugate partner to which the antibodies are attached may be any compound which retains its essential properties after reaction with the antibody, and which enables the antibody to substantially retain immunospecificity and immunoreactivity.

For example, when it is desired to attach an aldehyde of the oxidized carbohydrate portion of a glycoprotein to a conjugate compound, the compound should desirably contain a reactive group such as an amino or hydrazide group. Such conjugate compounds include various proteins, such as hormones, enzymes, transport proteins, catalysts, chelating compounds, receptor proteins and immunoglobulins and fluorescent or chemiluminescent compounds or potentially fluorescent or chemiluminescent compounds. By "potentially" fluorescent or chemiluminescent compounds is meant compounds which fluoresce or chemiluminesce only after reaction, modification or combination with another agent. Where a compound of interest does not contain an amino group, the compound can be modified to make an amino or hydrazide group available for coupling.

25

The compound to be attached to an antibody for use in a delivery system is selected according to the purpose of the intended application (e.g., killing, prevention of cell proliferation, hormone therapy, target imaging, or gene therapy, cell sorting, or separation schemes). Such compounds may include, for example, pharmaceutical agents, toxins, fragments of toxins, alkylating agents, enzymes, antibiotics, antimetabolites, antiproliferative agents, hormones, neurotransmitters, DNA, radioopaque dyes, radioactive isotopes, fluorogenic

35

compounds, marker compounds, lectins, compounds which alter cell membrane permeability, and insoluble matrices. Table I lists some of the pharmaceutical agents that may be employed in the herein described invention and in no way is meant to be an exhaustive list. Finally, a combination of compounds may be used.

5.3.2. SOLUBLE LINKERS

According to the invention, antibodies may be covalently attached to any compound of interest or an insoluble support through an intermediate soluble linking agent, or linker, having a number of reactive groups, one to react with antibody and one to react with the compound of interest or to an insoluble support. The linker must be chosen such that neither the reaction with antibody (or a compound of interest or insoluble support) nor the final product adversely affect antibody reactivity and selectivity. In general, these linkers would include heterobifunctional linkers such as mercaptoethanolamine which would bond to the oxidized antibody via its amino group. After deblocking the sulfur atom, free sulfhydryl groups would be available for further reaction. The linker may be of any appropriate size to permit the distance between the antibody and the compound of interest or insoluble support to be selected as desired.

5.3.3. INSOLUBLE SUPPORTS

Suitable insoluble supports may be attached directly to antibodies or indirectly through soluble linkers. Where one employs oxidized antibody for direct attachment to an amine-containing insoluble support, including such exemplary supports as any amine or hydrazide support, including derivatized dextrans,

agaroses, polystyrenes, polyvinyls, polyvinylalcohols, polyacrylamides and glasses, latices and other suitable polymers. These supports normally are employed as beads but may be surfaces of tubes and plates depending on the particular use.

5.4. CARRIER SYSTEMS

According to one embodiment of the present invention, a compound may be attached to an antibody directed against a target antigen. When release of the active form of the compound at the target site is desired, then the compound is attached to specific sites on an antibody molecule (immunoglobulin) belonging to a class that is capable of activating the complement cascade. This attachment is accomplished via chemical bonds (e.g., an ester or amide linkage) and linker groups (e.g., peptides or amino acids) which are susceptible to cleavage by one or more of the serum complement components.

20

The chemical linking methods described herein allow the resulting antibody conjugate to retain the ability to bind antigen and to activate the complement cascade. As a result, when the conjugate is administered to an individual, the subsequent formation of immune complexes with target antigens in vivo activates the individual's serum complement. If the linker is designed to be susceptible to cleavage by complement, the compound will be cleaved at the target site by one or more of the enzymes of the complement cascade. Since release of the compound occurs after delivery to the target site the efficiency of the target delivery system is greatly improved.

35

The method of the present invention offers another advantage over other targeting systems. It is known that all cells of a tumor do not each possess the target antigenic determinant. Thus, delivery systems
5 which require internalization into the target cell will effect successful delivery only to those tumor cells that possess the antigenic determinant and that are capable of internalizing the complex. Tumor cells that do not possess the antigenic determinant or are incapable of
10 internalization, will escape treatment.

According to the method of the present invention, antibody carrier molecules deliver the compound to the target cells. More importantly, however, once attached to
15 the target cell, the method described in the present invention allows the release of the active compound by the individual's activated complement enzymes. Once released, the compound is then free to permeate the target sites, e.g., tumor mass. As a result, the compound will act on
20 tumor cells that do not possess the antigenic determinant as well as those tumor cells that do possess the determinant. Additionally, the entire process is not dependant upon internalization of the conjugate.

25 The method of targeted delivery described herein may be employed for a number of purposes. The choice of antibodies, linkers, and compounds used to make the conjugates depends upon the purpose of delivery. The delivery and release of pharmaceutical compounds at
30 specific target sites may result in selectively killing or preventing the proliferation of tumor cells, cancer cells, fungi, bacteria, parasites, or virus. The targeted delivery of hormones, enzymes, or neurotransmitters to selected sites may also be accomplished. Ultimately the
35 method of the present invention may have an application in

gene therapy programs wherein DNA or specific genes may be delivered in vivo or in vitro to target cells that are deficient in that particular gene.

5 In an alternate embodiment, the conjugate may be designed so that the compound is delivered to the target but not released. Thus, the present invention may also be used for locating, detecting, and quantitating specific sites in vivo and in vitro such as tumors, organs, or
10 sites of infection. This embodiment of the invention is particularly useful in imaging systems, cell sorting techniques, and separation schemes.

 Specifically, in the case of imaging, a
15 radiopharmaceutical or heavy metal is (a) covalently bound to the linker or (b) non-covalently bound to the linker via a chelator. Therefore, depending upon the nature of the target and purpose of delivery, a wide range of antibodies, linkers, and compounds of interest may be used
20 in a variety of combinations.

5.5. SERUM COMPLEMENT AND SELECTION OF LINKERS

 According to the method of the present invention,
25 when release of a compound is desired, that compound is linked to a specific site on an antibody of the IgM class or certain subclasses of IgG (FIG. 1). The resulting conjugate retains the ability to bind antigen and activate the complement cascade.

30

 Complement is the collective name for a group of serum proteins which can be activated in one of two ways, the classical pathway and the properdin pathway (Müller-Eberhard, Hospital Practice, August 1977:33-43).
35 The classical pathway is initiated by the binding of

antibodies of the IgM class or certain subclasses of IgG to its corresponding antigen whereas the properdin pathway is dependent upon the serum protein, properdin and other non-immunoglobulin serum factors (Reid and Porter, 1981, 5 Ann. Rev. Biochem. 50:433-464).

The classical pathway is the pathway of particular importance for the practice of the present invention. The classical pathway is characterized by the 10 formation of certain antibody-antigen complexes (or immune complexes) which activate the proteolytic enzymes of the complement system (Borsos and Rapp, 1965, J. Immunol. 95:559-566; Cohen, 1968, J. Immunol. 100:407-413; Cohen and Becker, 1968, J. Immunol. 100:403-406; Ishizaka et 15 al., 1968, J. Immunol. 100:1145-1153). These activated complement enzymes cleave and activate other components of the complement cascade (FIG. 2). Ultimately the formation of an "attack complex" (or lytic complex) is induced resulting in disruption of target cell membrane integrity.

20 The first component activated in the classical pathway is C1 which becomes a protease that acts on both C2 and C4. Activated C1 ($C1\bar{}$) has a specific esterase activity. Activated C4,2 ($C4_{b,2_a}$), sometimes called C3 convertase, is a complex which proteolytically cleaves C3, 25 and together with activated C3 ($C3b$), cleaves C5. Cleavage of C3 is the first step in common between the classical and properdin pathways of complement activation.

30 The enzymatic activities of both $C1\bar{}$ and $C4_{b,2_a}$ have been recently studied using model synthetic substrates (see Table II) which are cleaved at the carboxy terminal ester or amide bond in vitro. These synthetic substrates may be used as linkers between an antibody 35 molecule and a compound as described in the present

invention. Such linkers will allow for the specific complement mediated cleavage and subsequent release of the compound in its active form at the target site. However, any substrate which is susceptible to cleavage by any of the components of complement may be used as a linker.

Thus, according to the present invention, a compound is joined to one end of the substrate linker group and the other end of the linker group is attached to a specific site on the antibody molecule. For example, if the compound has an hydroxy group or an amino group, the compound may be attached to the carboxy terminus of a peptide, amino acid or other suitably chosen linker via an ester or amide bond, respectively. For example, such compounds may be attached to the linker peptide via a carbodiimide reaction. If the compound contains functional groups that would interfere with attachment to the linker, these interfering functional groups can be blocked before attachment of the compound and deblocked once the conjugate is made. For example, FIG. 3 depicts a general reaction scheme for the attachment of the antineoplastic drug, Alkeran (Burroughs-Wellcome) to the peptide CBZ-gly-gly-arg. The opposite or amino terminal of the linker group is then modified for binding to an antibody molecule which is capable of activating complement.

The compound may be attached to the linker before or after the linker is attached to the antibody molecule. In certain applications such as attachment of short-lived radioisotopes to antibodies, it is desirable to first produce a stable modified antibody as an intermediate wherein the linker is free of an associated compound. Depending upon the particular application, the compound may be covalently attached to the linker of the modified

antibody. These peptide linkers may be variable in length since distance of the substrate from the antibody molecule may affect efficiency of cleavage which occurs at the amide or ester bond between the linker and the compound.

5 These linkers may also include organic compounds, for example, organic polymers of any desired length, one end of which can be covalently attached to specific sites on the antibody molecule. The other end of the organic polymer may be attached to an amino acid or peptide

10 linker. Table III lists other substrates that may be used as linker groups to prepare the antibody conjugates of the present invention. (In the table n may be an integer including zero.) These sequences were derived from those of the complement substrate sequences by substituting

15 amino acids with similar acid-base properties. This list is not exhaustive.

Thus when these conjugates bind to antigen in the presence of complement the amide or ester bond which

20 attaches the compound to the linker will be cleaved, resulting in release of the compound in its active form. These conjugates, when administered to an individual, will accomplish delivery and release of the compound at the target site, and are particularly effective for the in

25 vivo delivery of pharmaceutical agents, antibiotics, antimetabolites, antiproliferative agents, and cytotoxins.

In an alternate embodiment the conjugates of the present invention may be used to detect the target antigen

30 in vitro. For instance, if the conjugate is added to a test mixture containing the target antigen and serum complement, the resulting complement mediated release of the compound (e.g., a fluorescent compound) is an indication and measure of the presence of target antigen

35 in the test mixture.

TABLE IISYNTHETIC SUBSTRATES FOR COMPLEMENT COMPONENTS

5

Reference No.*For C1:

10	N-Boc-tyrosine o-nitrophenyl ester	1
	N-Boc-phenylalanine o-nitrophenyl ester	1
	α -N-Boc-lysine o-nitrophenyl ester.	1
	N-CBZ-tyrosine p-nitrophenyl ester	2

15

For C4_b, 2_a:

	N-acetyl-gly-lys-methyl ester	3
	α -N-CBZ-lys-methyl ester	3
20	α -N-acetyl-lys-methyl ester	3
	Boc-leu-gly-arg-7-amino-4-methylcoumarin	4

25

-
- * 1. Sim, et al., 1977, Biochem. J. 163:219-27.
 2. Bins, 1969, Biochemistry 8:4503-10.
 3. Cooper, N.R., 1975, Biochemistry 14:4245-51.
 4. Caporale, et al., 1981, J. Immunol. 128:1963-65.

30

35


TABLE III

LINKER GROUPS FOR ATTACHMENT OF
COMPOUNDS OF INTEREST (CI) TO ANTIBODY MOLECULES¹

5


A. Linkers For Cleavage by C_I

10




B. Tripeptide Sequences For Cleavage by C_{4b,2a}

15



20

25



30

35

III B. Tripeptide Sequences For Cleavage by $C4_{b,2_a}$
(Continued)

5	$H_2N-(a.a.)_n-$	$\left\{ \begin{array}{l} \text{-gly-ala-arg-} \\ \text{-gly-ala-lys-} \\ \text{-gly-ala-tyr-} \\ \text{-gly-leu-arg-} \\ \text{-gly-leu-tyr-} \\ \text{-gly-leu-lys-} \\ \text{-gly-gly-arg-} \\ \text{-gly-gly-lys-} \\ \text{-gly-gly-tyr-} \\ \text{-gly-val-arg-} \\ \text{-gly-val-lys-} \\ \text{-gly-val-tyr-} \\ \text{-gly-ile-arg-} \\ \text{-gly-ile-lys-} \\ \text{-gly-ile-tyr-} \end{array} \right\}$	$-*-CI$
10			
15	$H_2N-(a.a.)_n-$	$\left\{ \begin{array}{l} \text{-val-ala-arg-} \\ \text{-val-ala-lys-} \\ \text{-val-ala-tyr-} \\ \text{-val-leu-arg-} \\ \text{-val-leu-lys-} \\ \text{-val-leu-tyr-} \\ \text{-val-gly-arg-} \\ \text{-val-gly-lys-} \\ \text{-val-gly-tyr-} \\ \text{-val-val-arg-} \\ \text{-val-val-lys-} \\ \text{-val-val-tyr-} \\ \text{-val-ile-arg-} \\ \text{-val-ile-lys-} \\ \text{-val-ile-tyr-} \end{array} \right\}$	$-*-CI$
20			
25	$H_2N(a.a.)_n-$	$\left\{ \begin{array}{l} \text{-ile-ala-arg-} \\ \text{-ile-ala-lys-} \\ \text{-ile-ala-tyr-} \\ \text{-ile-leu-arg-} \\ \text{-ile-leu-lys-} \\ \text{-ile-leu-tyr-} \\ \text{-ile-gly-arg-} \\ \text{-ile-gly-lys-} \\ \text{-ile-gly-tyr-} \\ \text{-ile-val-arg-} \\ \text{-ile-val-lys-} \\ \text{-ile-val-tyr-} \\ \text{-ile-ile-arg-} \\ \text{-ile-ile-lys-} \\ \text{-ile-ile-tyr-} \end{array} \right\}$	$-*-CI$
30			
35			

III C. Peptide Sequences for Cleavage by C_{4b,2a}

5		-leu-gly-	
		-leu-leu-	
		-leu-ala-	
		-leu-val-	
		-leu-ile-	
		-gly-gly-	
		-gly-leu-	
		-gly-ala-	
		-gly-val-	
		-gly-ile-	
10	H ₂ N-	-ala-gly-	-Tripeptide ² -*-CI
		-ala-leu-	
		-ala-ala-	
		-ala-val-	
		-ala-ile-	
		-val-gly-	
		-val-leu-	
		-val-ala-	
15		-val-val-	
		-val-ile-	
		-ile-gly-	
		-ile-leu-	
		-ile-ala-	
		-ile-val-	
20		-ile-ile-	

1 The asterisk (*) represents either an amide bond (Linker-C-NH-CI) or an ester bond (Linker-C-O-CI).


2 Tripeptide represents any of the Tripeptides listed in Table III B.

25

30

35

In certain applications, release of the compound is not desirable. Thus, under an alternate embodiment of the present invention a compound is attached to antibody molecules via linkers which are not susceptible to
5 cleavage by complement enzymes. These linkers may include amino acids, peptides, or other organic compounds which may be modified to include functional groups that can subsequently be utilized in attachment to antibody molecules or antibody fragments by the methods described
10 herein. A general formula for such an organic linker is




wherein W is either $-NH-CH_2-$ or $-CH_2-$;
15 Q is an amino acid, peptide, chelator (e.g., diethylenetriaminepentaacetic acid) or chelator derivative ; and
n is an integer from 0 to 20.

20 Alternatively, a compound may be attached to antibody molecules or antibody fragments which do not activate complement. When using carrier antibodies that are incapable of complement activation, this attachment may be accomplished using linkers that are susceptible to
25 cleavage by activated complement or using linkers that are not susceptible to cleavage by activated complement. The non-cleavage approach may be used to attach antibody molecules or fragments to immobilized or insoluble matrices, e.g., agarose, polyacrylamide, etc. These
30 products may then be used to identify or separate specific antigenic components from complex mixtures. This technique may be accomplished by allowing a mixture which is suspected to contain antigen to contact the immobilized antibody conjugates. After washing off all nonreacting
35 components, the target antigen may be removed from the

insoluble matrix by treatment with a denaturant or chaotropic agent that is capable of dissociating antigen-antibody complexes.

5 This non-cleavage approach is also particularly useful for making antibody conjugates for use in cell sorting techniques (Loken and Herzenberg, 1975, Annals N.Y. Acad. Sci. 254:163-171) and in imaging systems for
10 locating tumors, organs, sites of infection, etc., where release of the compound is not desirable. In such imaging systems, the use of antibody fragments offers a distinct advantage since such fragments diffuse and permeate tissue masses more easily than do whole antibody molecules. In
15 addition, antibody fragments do not cross placental barriers (Bellanti, 1978, Immunology II. W.B. Saunders, Philadelphia). Therefore, tumor imaging may be practiced in pregnant females.

20 In still another embodiment, it may be necessary to construct the linker in such a way as to optimize the spacing between the compound and the antibody. This may be accomplished by use of a linker of the general structure



25 wherein Q is an amino acid or peptide and W and n are as described above.

30 In yet another application of target delivery, a release of the compound without complement activation is desired since activation of the complement cascade will ultimately lyse the target cell. Hence, this approach is useful when delivery and release of the compound should be accomplished without killing the target cell. Such is the
35 goal when delivery of cell mediators such as hormones,


enzymes, corticosteroids, neurotransmitters, genes or enzymes to target cells is desired. These conjugates may be prepared by attaching the compound to an antibody molecule or fragment that is not capable of activating complement via a linker that is mildly susceptible to cleavage by serum proteases. When this conjugate is administered to an individual, antigen-antibody complexes will form quickly whereas cleavage of the compound will occur slowly, thus resulting in release of the compound at the target site.

The first steps in activation of the classical complement pathway require an interaction between C1 and antibody-antigen complexes. This interaction requires that a site in the Fc region of the antibody molecule be present (FIG. 1). Some of the carbohydrate moieties are located on the Fc region of the immunoglobulin which are required in order for C1 binding to occur. Removal of the carbohydrate moiety results in loss of the ability of the immune complex to bind component C1 of complement (Winkelhake et al., 1980, J. Biol. Chem. 255:2822-2828). The Fab or Fab' fragments of any immunoglobulins which contain carbohydrate moieties may be utilized in the reaction scheme described herein. An example of such an immunoglobulin is the human IgM sequenced by Putnam, et al. (1973, Science 132:287).

In accordance with one embodiment of the invention, the substrate linkers are modified by attaching hydrazine or hydrazide derivatives to one end of the linker. The unmodified sites on the linker may or may not be covalently attached to a compound. For instance, the substrate linkers which are attached to a compound via an ester or amide link, as described in Section 5.5 (see Table II and Table III) are modified by attaching a


hydrazide (e.g., phenylhydrazine) to the opposite amino terminus of the peptide chain. This results in the following structure (N.B., the symbol * signifies an amide or ester bond):

5



Although in the structure shown the hydrazine is in the para position, one could alternatively use compounds with the hydrazine moiety in the ortho or meta positions. These hydrazide derivatives of the peptide linkers which are attached to a compound via an ester or amide link are then reacted with an oxidized immunoglobulin, or immunoglobulin fragment containing an oxidized carbohydrate. This results in hydrazone formation and the covalent attachment of the compound to the carbohydrate side chain of the immunoglobulin via a linker group which is susceptible to cleavage by complement. If desired, the linker utilized may be resistant to cleavage by either activated complement or serum proteases (e.g. a linker which includes a chelator or chelator derivative for use in an imaging system). In another application the linker may be designed to be susceptible to cleavage by a serum protease. The covalent attachment of the linker to the carrier antibody as described herein does not interfere with the antigen binding site of the molecule nor with complement fixation. The resulting structure is schematically represented below (N.B., the symbol * signifies an amide or ester bond):

30



Although this section is directed primarily to reactions with the carbohydrate moieties of antibodies,

35

such techniques are applicable to other classes of glycoproteins as well.

5.6. ADDITIONAL USES OF ANTIBODY CONJUGATES

5

The antibody conjugates of the invention are useful for a variety of applications in medicine and industry, including separations and affinity purification, as well as diagnostics and therapeutics, in immunoassays, cell sorting, electrophoretic analysis, histology, cytology and the like. All of these applications capitalize on the ability of antibodies to distinguish specifically between chemical compounds of slightly differing structure.

15

The novel antibody conjugates of the invention find use in any immunoassay where the interaction between antibody and antigen provides a detectible signal or a means for modulating a detectible signal. The signals can be chemical, electromagnetic radiation, particularly ultraviolet or visible light, either absorption or emission, thermal, volumetric, electrochemical or the like. The modulation of the signal can be, for example, as a result of quenching or modification of fluorescence or chemiluminescence, where the conjugate partner is fluorescent or chemiluminescent (or potentially fluorescent or chemiluminescent).

In immunoassays, the antigen of interest is normally labeled or tagged in some manner and the assay allows for discrimination between the amount of labeled or tagged antigen which is bound to antibody and the amount of labeled or tagged antigen which is unbound. In homogeneous assays, the discrimination is a result of modulation of the signal provided by the label or tag. In

heterogeneous assays, the discrimination is a result of physical separation of bound and unbound antigen.

6. EXAMPLES: SERIES I

5

The following examples illustrate methods for the specific attachment of an antibody molecule to a compound of interest via an intermediate soluble linker.

10

6.1. OXIDATION OF THE CARBOHYDRATE
MOIETY OF THE ANTIBODY MOLECULE

15

20

The antibody molecule used in this example was a monoclonal IgM (designated no. 171) specific for antigenic determinants on sheep red blood cells. To prepare the monoclonal antibody, Lewis rats were immunized with a single injection of sheep red blood cells. Three days later, spleen cells from the immunized rats were harvested and fused with the myeloma line SP2/0 Ag14 according to the method of McKearn, et al., 1979, Immunol. Rev. 47:91-115. Cloned cells were then grown and the resulting monoclonal antibody was purified as described by Klinman and McKearn, 1981, J. Immunol. Meth. 42:1-9.

25

30


35

Oxidation of the antibody carbohydrate moiety was accomplished by reacting the antibody with galactose oxidase by a modification of the method of Cooper, et al., supra. To this end, 3.8 mg of no. 171 monoclonal antibody was added to 1 ml of buffer consisting of 0.135M NaCl, 0.015M Tris-HCl (pH 7.0), 0.5mM MgCl₂, and 0.15mM CaCl₂. Subsequently, a 0.1 ml aliquot of a solution of galactose oxidase (Worthington Biochemical Co., Freehold, N.J.) at a concentration of 52 units of enzyme/ml of the same buffer was added to the antibody solution. Finally, 43 µg of catalase (Worthington Biochemical Co., Freehold,

N.J.) dissolved in an additional 0.1 ml of the same buffer was added to the reaction mixture (the catalase was added to degrade hydrogen peroxide that is generated during the oxidation reaction). The reaction mixture was incubated for 48 hours at room temperature, then stored at 4°C. FIG. 4 represents the excitation spectra for unoxidized (a) and oxidized (b) antibodies.

6.2. PREPARATION OF THE TRIPEPTIDE-AMC FOR ATTACHMENT TO THE ANTIBODY MOLECULE

For the purposes of the present example, a synthetic fluorogenic compound was utilized as the conjugate partner. The properties of this synthetic compound are such that the bound and free states of the fluorogenic compound are spectrofluorometrically distinguishable. The synthetic fluorogenic compound used was obtained from Serva Fine Biochemicals, Inc., Garden City Park, L.I., N.Y. (Catalog #51474). This compound consists of a tripeptide (Gly-Gly-Arg) attached via an amide linkage to the fluorescent compound 7-amino-4-methyl coumarin (AMC); the amino group of glycine is blocked by carbobenzoxy chloride (Cbz). The structure of this compound (herein called Tripeptide-AMC) is shown below:



The excitation and emission maxima of free AMC (345 nm and 445 nm, respectively) differ from those for AMC bound to the tripeptide (325 nm and 395 nm, respectively). This affords a means for distinguishing


between the bound and free forms of the AMC molecule using a fluorometric assay. Excitation and emission wavelengths of 383 nm and 455 nm may be used for optimum differences for assay purposes; at these wavelengths, free AMC retains
5 20% of its maximal fluorescence but possesses a relative fluorescence 500-fold greater than an equimolar amount of bound AMC (Zimmerman, et al., 1978, Proc. Natl. Acad. Sci., U.S.A. 75(2):750-753).

10 In order to effect specific bonding of the Tripeptide-AMC to the oxidized carbohydrate moiety of the antibody prepared in Section 6.1, a hydrazine derivative was linked to the terminal glycine of the Tripeptide-AMC
15 compound. The presence of the hydrazine group is advantageous since this results in reactivity for the oxidized carbohydrate moiety of the antibody molecule under very mild conditions while not affecting the antigen binding site. Aldehyde groups of the oxidized
20 carbohydrate side chain of the antibody molecule then react with the hydrazine derivative to form a hydrazone.

In order to attach a hydrazine derivative (e.g., 4-fluorophenylhydrazine), the Tripeptide-AMC was first deblocked at the glycine amino terminus by removal of the
25 Cbz group. This was accomplished by dissolving the Tripeptide-AMC in trifluoroacetic acid (Sigma, St. Louis, Mo.), and bubbling HBr gas (Matheson, East Rutherford, N.J.) through the solution for 45 minutes. The product, H_2N -Gly-Gly-Arg-NH-AMC, was precipitated by the addition
30 of cold diethyl ether (Baker Chemical Co., Phillipsburg, N.J.), and dissolved in absolute ethanol (Publicker Industries Co., Linfield, Pa.). An equimolar amount of 4-fluorophenylhydrazine (Aldrich Chemical Co., Milwaukee, Wis.) in absolute ethanol was added with mixing. After
35 incubation in the dark at room temperature for 2 hours,

the reaction mixture was stored in the dark at 4°C. The resulting product (Phenylhydrazine-Tripeptide-AMC) has the structure:

5



This compound was shown to be positive for fluorescence by exciting with ultraviolet light, and positive for the presence of a hydrazine group. The hydrazine linked to the tripeptide was detected by thin layer chromatography (TLC) using a spray of a 0.1% trinitrobenzene sulfonic acid aqueous solution for the colorimetric determination of a hydrazine (a pinkish or orange-brown color indicates the presence of hydrazine). The results of TLC demonstrated the presence of a hydrazine group at the migratory band of the Tripeptide-AMC.

The absorption and emission spectra for the Phenylhydrazine-Tripeptide-AMC compound as shown in FIG. 5 reveal a similarity to the Tripeptide-AMC spectra but a shift in excitation and emission maxima consistent with the covalent modification of the Tripeptide-AMC. The maxima for excitation and emission of the Phenylhydrazine-Tripeptide-AMC compound are 345 nm and 385 nm, respectively. The product was precipitated from solution with cold diethyl ether, washed, and dissolved in dimethylsulfoxide (Baker Chemical Co., Phillipsburg, N.J.),

6.3. COVALENT ATTACHMENT OF PHENYLHYDRAZIDE-TRIPEPTIDE-AMC TO THE OXIDIZED CARBOHYDRATE MOIETY OF THE ANTIBODY MOLECULE

The oxidized monoclonal antibody preparation, described in Section 6.1, supra, was adjusted to pH 5.1 by

the addition of a small amount of 0.1M acetate buffer (pH 5.0). An estimated 10-fold excess of Phenylhydrazine-Tripeptide-AMC (prepared in Section 6.2) was added to the antibody solution, which was then incubated at 37°C in the dark, overnight (approximately 14 hours). The reaction mixture was then chromatographed on a Sephadex G-25 column (Pharmacia Fine Chemicals, Piscataway, N.J.) in order to remove any unreacted Phenylhydrazine-Tripeptide-AMC.

Spectrofluorometric analysis of the protein fractions confirmed the presence of the Phenylhydrazine-Tripeptide-AMC covalently attached to the antibody (now called Antibody-Phenylhydrazine-Tripeptide-AMC, or antibody conjugate). The excitation and emission maxima for the conjugate are 325 nm and 385 nm, respectively (FIG. 6). The large peak at 285 nm in the excitation spectrum of the conjugate may be explained by tryptophan absorption with residual fluorescence at 385 nm and may also be the result of resonance energy transfer from the amino acid tryptophan of the antibody molecule to AMC.

7. EXAMPLES: SERIES II

The purpose of this series of examples is to demonstrate that methods for preparing antibody conjugates of the invention do not adversely affect the antigen binding properties of antibodies in the way the carbodiimide reaction affects such properties. To this end, the carbohydrate of a mouse monoclonal IgM, specific for the phosphorylcholine group, was oxidized and covalently attached to the 1,6-diaminohexyl derivative of ethylene diamine di-(o-hydroxyphenylacetic acid) [EDDHA] to form 1,6-diaminohexyl-EDDHA. For comparative purposes, 1,6-diaminohexyl-EDDHA as well as unmodified EDDHA were attached to identical samples of the IgM monoclonal

antibody using the carbodiimide reaction. Under these conditions, the 1,6-diaminohexyl-EDDHA would couple to available aspartic and glutamic acid residues, while the unmodified EDDHA would couple to available lysines.

5

The binding properties of these samples were compared with the native antibody in order to evaluate affinity and homogeneity.

10

7.1. OXIDATION OF MOUSE MONOCLONAL IgM

A mouse monoclonal IgM antibody specific for the ligand, phosphorylcholine, was oxidized at a concentration of 2 mg/ml in phosphate buffered saline (PBS, 0.01M phosphate, 0.15M sodium chloride), pH 7.0. The antibody-containing solution was cooled in a water-ice bath, and 56.8 µg of sodium metaperiodate was added (40 µl of a 1.42 mg/ml solution; final periodate concentration = 0.26mM). This reaction mixture was incubated for one hour, after which 2 µl of ethylene glycol was added. This was incubated an additional thirty minutes. The sample was then passed through a Sephadex G-25 column equilibrated with PBS and the protein fractions pooled.

25

7.2. ATTACHMENT OF LINKER TO EDDHA

EDDHA (1.5 g, 4.2 mmole) and triethylamine (1.2 ml, 8.4 mmole) were mixed with 40 ml of water. This heterogeneous solution was heated to 60°C and stirred vigorously for 0.5 hour. The solution was dried in vacuo and then was dissolved in 400 ml of dry N,N-dimethylformamide. The solution was then cooled in an ice bath and isobutylchloroformate (0.56 ml, 4.2 mmole) was added. The reaction mixture was stirred with cooling for 0.5 hours. The resulting triethylamine hydrochloride

35

precipitate was removed by filtration and the filtrate containing mixed carboxycarbonic anhydride of EDDHA was red in color.

5 1-amino-6-trifluoroacetamidohexane (0.8 g, 4.1 mmole) was added to the above carboxycarbonic anhydride of EDDHA. The homogeneous solution was stirred at 4°C for 0.5 hour, then was lyophilized to yield an oily product. The oil was washed with acetone/ether (4:1) mixture to
10 yield a crude yellow product. The solid 1-amino-6-trifluoroacetamidohexyl-EDDHA was collected and hydrolyzed with 7% K_2CO_3 and reprecipitated with HCl at pH 4 to yield pure 1,6-diaminohexyl-EDDHA (1.4 g). This compound gives a positive test of ninhydrin and thin
15 layer chromatography shows only one spot. In the presence of basic solution of an equal molar quantity of $TbCl_3$, excitation at 295 nm yielded emission at 545 nm, due to formation of the characteristic energy transfer chelate complex between EDDHA and terbium ion.

20

7.3. PREPARATION OF IgM-LINKER-EDDHA CONJUGATES

The antibody, oxidized by the method of Section 7.1, was incubated with an approximately 270-fold molar
25 excess of 1,6-diaminohexyl-EDDHA, prepared by the method of Section 7.2, for one hour at room temperature. This was followed by addition of solid sodium cyanoborohydride to a final concentration of 10mM, and further incubation of 4 hours at room temperature. The mixture was then
30 dialyzed at 4°C versus several changes of PBS, and concentrated by ultrafiltration.

7.4. CARBODIIMIDE ATTACHMENT OF LINKER-EDDHA TO IgM

To 263 μ l IgM antibody (1.9 mg/ml) was added 10 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (1 ml of 10 mg/ml solution, pH 5.0) and PBS (pH 5.0) to make up to 2.5 ml. The mixture was incubated for two hours at room temperature. Then 275 μ l of 0.1M 1,6-diaminohexyl-EDDHA in 2.5 ml water (pH 5.5) was added and the solution incubated two hours at room temperature. Ten μ l of 1M ethanolamine was then added and incubated for one hour at room temperature. This was then dialysed overnight against PBS (pH 7.0).

7.5. CARBODIIMIDE ATTACHMENT OF EDDHA TO IgM

15

To 263 μ l IgM antibody (1.9 mg/ml) was added 10 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (1 ml of 10 mg/ml solution, pH 5.0) and PBS (pH 5.0) to make up to 2.5 ml. The mixture was incubated for two hours at room temperature. To this was added 2.75 ml of 0.01M EDDHA (pH 5.5) and the solution was incubated for two hours at room temperature. Ten μ l 1M ethanolamine was added and the mixture incubated for one hour at room temperature. This was then dialysed overnight against PBS (pH 7.0).

7.6. EFFECTS OF CARBOHYDRATE-MEDIATED ATTACHMENT OF ANTIBODIES

30

The affinities of unmodified mouse monoclonal antibody and antibody conjugates prepared according to Sections 7.3, 7.4 and 7.5, all specific for the phosphorylcholine group, were measured by fluorescence quenching using a Perkin-Elmer Model 512 Double Beam Fluorescence Spectrometer (Perkin-Elmer Corporation,

35

Norwalk, Connecticut). The excitation and emission wavelengths were 295 and 345 nm, respectively, and the temperature was maintained at 25°C with a Lauda K-2/R circulating water bath (Brinkmann Instruments).

5 Antibody concentrations were calculated using an $\epsilon_{280}^{1\%} = 13.5$ and ranged from 7.5×10^{-8} to 9.7×10^{-8} M. All binding sites were assumed to be active and the sample volumes were 3.0 ml. The stock concentrations of the ligand, N-(2,4-dinitrophenyl)-p-aminophenylphosphorylcholine (DPPC), was 1.17×10^{-4} M. 10 The titrations were done in phosphate-buffered saline at pH 7.4. The ligand was added continuously, with stirring, at a rate of 9.01 $\mu\text{l}/\text{min}$ using a motor-driven syringe, and 15 the fluorescence intensity was monitored by a CBM 2001 series computer equipped with a 2040 dual drive floppy disk and a 2023 printer (Commodore Business Machines), interfaced with a Preset I, analog/digital converter (Connecticut Microcomputers). To correct for attenuation and sample dilution, a non-specific human Waldenström's 20 macroglobulin or anti-lactose murine hybridoma antibodies [Mandal and Karush, 1981, J. Immunol. 127:1240] were titrated. A total of 180 μl of ligand solution as added per titration. Binding parameters were calculated using 25 Sips distribution function [Sips, 1948, J. Chem. Phys. 16:490] in a reiterative manner, in which the maximum quench was allowed to vary until the heterogeneity index was within 0.002 of unity.

30 The calculation of the Q_{max} values involves a significant uncertainty, probably not less than 10%, due to the reiterative procedure used to generate them. This uncertainty arises from the fact that any discrepancy between the actual concentration of active sites and that 35 calculated from the optical density is compensated for in the derived value of Q_{max} when the criterion of a

heterogeneity index of unity is employed. This compensation results from the dependence of the concentration of bound ligand on the ratio of antibody concentration to the value of Q_{\max} . Because of this
5 dependence the accuracy of the derived values of the association constants is not limited by the concentration of active sites.

The Sips plots presenting data for unmodified
10 antibody carbodiimide conjugates and antibody conjugates of the invention are shown in FIG. 7. The binding measurements clearly demonstrate the retention of specificity, affinity, and homogeneity for the sample modified via the carbohydrate attachment methods of the
15 invention (Δ - Δ), when compared to the unmodified antibody (\bullet - \bullet). The association constant for the binding of the phosphorylcholine derivative was measured to be $0.1 \times 10^5 \text{ M}^{-1}$ for the unmodified antibody and $1.1 \times 10^6 \text{ M}^{-1}$ for the carbohydrate-attached antibody
20 conjugate. In contrast to this, an antibody preparation modified by the carbodiimide reaction (\square - \square) has substantially reduced binding, certainly well below the calculated values of $1-2 \times 10^5$. The assumption of a heterogeneity index of unity in the Sips analysis is valid
25 for the data reduction only if the sample is homogeneous (monoclonal). A check on the actual homogeneity (monoclonal nature) of the sample is the correlation coefficient or fit if the experimental data points with the calculated line in the Sips plot. Inspection of the
30 plots of FIG. 7 clearly show good agreement for the unmodified antibody and carbohydrate-attached antibody and very poor agreement for those with carbodiimide-attachments. This is most likely due to the lack of selectivity of the carbodiimide attachment
35 method. Lysines, glutamic and aspartic acids occur in all

parts of antibody molecules, including the antigen binding regions. As a result, at least some of the antibodies are modified at or near the binding sites with consequent effects or interaction with antigen. The sites of
5 attachment to carbohydrate, however, are specific and distal from the binding site, and provide little, if any, change in binding properties observed in these experiments. While obtained for covalently modified antibodies in solution, it is believed that the
10 conclusions of this study may be extended to immobilized antibodies as well (identical experiments with immobilized antibodies cannot be done for technical reasons). The random nature of commonly used attachment chemistries (cyanogen bromide activated gels, glutaraldehyde beads,
15 N-hydroxysuccinimide ester gels, etc.) ought to yield matrices with reduced binding capacity when compared with site-specific attachments of the invention.

8. EXAMPLES: SERIES III

20 The purpose of this series of Examples is to provide evidence that antibody may be attached to insoluble supports with high efficiency via carbohydrate moieties of the antibody, and that the attached antibody
25 retains specific antigen binding capacity.

8.1. ANTIBODY ATTACHMENT TO AMINOHEXYL-SEPHAROSE

30 IgM and IgG antibodies were oxidized using periodate as described in Section 7.1, except that Sepharose CL-4B (Pharmacia Fine Chemicals, Inc., New Market, New Jersey) was used in place of ethylene glycol to quench the reaction. After removal of the Sepharose
35 CL-4B, the antibody was added to aminohexyl-Sepharose

CL-4B (Pharmacia Fine Chemicals, Inc.) and stirred at room temperature for thirty minutes. Sodium cyanoborohydride was added to a final concentration of 5mM and the mixture was stirred for sixteen hours. The resultant antibody-bound resin (Ab-CHO-SEPH) was washed extensively with PBS. The amount of antibody bound to the aminoethyl-Sepharose was determined by use of ^{125}I -IgG and ^{125}I -IgM antibody. Table IV shows that immobilization of antibody via the carbohydrate moieties of the antibody occurs at a high degree of efficiency.

TABLE IV

Immobilization of Antibodies to
Aminoethyl-Sepharose

<u>Antibody</u>	<u>mg Antibody</u> <u>ml Sepharose</u>	<u>% Binding Efficiency*</u>
IgG	7.8	85
IgM	4.6	91

$$* \quad \% \text{ Binding Efficiency} = \frac{\text{mg antibody bound}}{\text{mg antibody added}} \times 100$$

8.2. SEPARATIONS

Mouse monoclonal IgG antibody against the 2,4-dinitrophenyl (DNP) haptenic group was oxidized and attached to aminoethyl-Sepharose (Ab-CHO-SEPH) according to the method outlined in Section 8.1. The antibody was also attached to cyanogen bromide-activated Sepharose (Ab-CNBr-SEPH) according to Cuatrecasas, et al. [1968, Proc. Natl. Acad. Sci., U.S.A. 61:636].

Ribonuclease conjugated with the DNP group (DNP-RNase) was prepared by mixing equimolar amounts of 2,4-dinitrofluorobenzene (Aldrich Chemical Co., Inc., Milwaukee, Wisconsin) and ribonuclease (Sigma Company, St. Louis, Missouri) in 0.1M carbonate buffer, pH 9.0, for four hours at room temperature. After extensive dialysis against PBS, the DNP-RNase was determined to have an average of 0.8 moles of the DNP group per mole of ribonuclease. The DNP-RNase was radiolabeled with ^{125}I by the use of chloramine-T (Aldrich Chemical Co., Inc.).

The two immobilized anti-DNP antibody resins, Ab-CHO-SEPH and Ab-CNBr-SEPH, were then tested for their binding capacity of ^{125}I -DNP-RNase. The two antibody preparations had a very high binding affinity for DNP-RNase as evidenced by the inability of 3M sodium thiocyanate to release bound DNP-RNase from either preparation. Therefore, in order to modify the system so that antigen binding would be reversible, experiments were performed in the presence of 4M urea. The data in Table V shows antibodies immobilized by the way of carbohydrate attachment (Ab-CHO-SEPH) bind DNA-RNase more effectively than the same antibodies immobilized by the way of lysine residues (Ab-CNBr-SEPH).

25

30

35

TABLE V

5 Binding of DNP-RNase to Immobilized
Antibody Resins*

	<u>Resin</u>	<u>mg Antibody</u> <u>ml Resin</u>	<u>µg DNP-RNase bound</u> <u>mg Antibody</u>	<u>% DNP-RNase⁺</u> <u>Binding</u>
10	Ab-CNBr-SEPH	2.0	3.9	100
	Ab-CHO-SEPH	0.6	5.5	140

* Forty µl of a 50% v/v slurry of either Ab-CHO-SEPH or Ab-CNBr-SEPH resin was incubated with 2 µg of ¹²⁵I-DNP-RNase in 4M urea, 0.15M NaCl, 0.01M potassium phosphate, pH 7.4 (urea-PBS) at 22°C for 120 minutes. The total volume of the assay was 0.4 ml. After incubation, the resin was washed with urea-PBS. The ¹²⁵I-DNP-RNase bound to resins was determined by counting the resins in a LKB 1271 gamma counter.

$$20 \quad + \quad \% \text{ of DNP-RNase Binding} = 100 \times \frac{\frac{\mu\text{g DNP-RNase bound}}{\text{mg Ab on resin}}}{\frac{\mu\text{g DNP-RNase bound}}{\text{mg Ab on Ab-CNBr-SEPH}}}$$

25 9. EXAMPLES: SERIES IV

The following examples illustrate a method for the specific attachment to an antibody molecule of a peptide linked to a compound of interest (compound) via an amide or ester bond. The resulting antibody conjugate retains the ability to fix complement as revealed by a hemolytic complement fixation assay. Furthermore, the specific release of the compound at the antigenic cell surface via enzymatic cleavage by the complement system is demonstrated by a non-hemolytic assay.

In the following examples the compound is fluorogenic. Thus, the complement mediated release of the fluorescent compound may be detected by an assay capable of differentiating between the bound and free forms of the fluorescent molecule.

The materials and procedures of Section 6.1 were used as described to oxidize the carbohydrate moieties of monoclonal antibodies (No. 171).

10

In the presence of sheep red blood cells and serum complement, these monoclonal antibodies (No. 171) activate the complement enzyme cascade (a result of antigen-antibody binding). Complement fixation causes lysis of the sheep red blood cells which results in the release of hemoglobin. The released hemoglobin may be detected spectrophotometrically, thus providing an assay for complement fixation.

20

The tripeptide-AMC was prepared as described in Section 6.2. The properties of the fluorogenic compound (AMC) are such that the bound and free states of the fluorogenic compound are spectrofluorometrically distinguishable. This provides a definitive assay for measuring the complement fixation ability of the antibody conjugate. More importantly, it provides a means for quantitating the subsequent complement-mediated release of the compound.

30

The specific covalent attachment of phenylhydrazine-tripeptide-AMC to the oxidized carbohydrate moieties of the antibodies was performed as described in Section 6.3.

35

9.1 COMPLEMENT FIXATION ASSAYS

Two types of complement fixation assays were utilized, hemolytic and fluorometric. These assays
5 determined whether the Antibody-Phenylhydrazine-Tripeptide-AMC conjugate retained complement fixation ability, and whether AMC was cleaved by complement.

9.1.1 PREPARATION OF HUMAN COMPLEMENT

10

A 10 ml sample of freshly drawn human whole blood was clotted on ice for 17 hours. The clot was removed by centrifugation, and the resulting human serum was frozen in 0.5 ml aliquots. Human complement was shown to be
15 active in these samples by the hemolytic assay described in Section 9.1.2.

9.1.2. HEMOLYTIC ASSAY FOR COMPLEMENT FIXATION

20

A 200 µl aliquot of a suspension of sheep red blood cells (Gibco Diagnostics, Madison, Wis.) at an approximate concentration of 2×10^8 cells/ml were mixed with 20 µl of the antibody conjugate mixture prepared in
25 Section 6.3 (approximately 2 µg of protein). After 15 minutes of mixing and incubating at 37°C, 100 µl of the human serum complement (prepared in Section 9.1.1) was added to the mixture. After 30 min to 1 hour of incubation at 37°C, the mixture was centrifuged to pellet
30 the cells. The extent of complement-mediated cell lysis was determined by spectrophotometrically measuring hemoglobin released into the supernatant (412 nm).

The results of this assay demonstrated complete
35 hemolysis and essentially 100% binding of antibody to cell

surface. For example, addition of distilled water to a pellet formed by centrifuging 200 μ l of the sheep red blood cell suspension completely lyses the cells, and releases hemoglobin. A 1:20 dilution of the supernatant of sheep red blood cells which were completely lysed in distilled water had an O.D.₄₁₂ of 0.646. An identical dilution of sheep red blood cells which were lysed by the addition of conjugate and complement had an O.D.₄₁₂ of 0.672. Thus the conjugate retained the ability to bind antigen and to fix complement.

9.1.3 NON-HEMOLYTIC ASSAY FOR COMPLEMENT
MEDIATED RELEASE OF AMC

Conditions for the non-hemolytic assay were identical to those above except that glutaraldehyde-fixed sheep red blood cells (Sigma, St. Louis, Mo.) were used in place of normal sheep red blood cells. Glutaraldehyde fixed cells do not lyse in the presence of antibody and complement and, therefore, no hemoglobin is released. Instead, a fluorometric assay is used to demonstrate the release of the AMC. A non-hemolytic system is necessary for use in the fluorometric assay, because the presence of hemoglobin interferes with fluorescence measurements in this system. Prior to use in the assay, these fixed red blood cells were shown to bind both the unmodified antibody and the Antibody-Phenylhydrazine-Tripeptide-AMC which was prepared in Section 6.3.

The non-hemolytic assay was used to show the specific complement-mediated release of the AMC from the antibody conjugate. Similarly to the hemolytic assay, 200 μ l of the glutaraldehyde-fixed sheep red blood cells, at an approximate concentration of 2×10^8 cells/ml, was

incubated with the Antibody-Phenylhydrazide-Tripeptide-AMC conjugate at 37°C for 15 minutes.


After centrifuging and resuspension in buffer,
5 50 µl of the human complement preparation (Section 9.1.1) was added, and the fluorescence at 460 nm monitored, with excitation at 380 nm (Caporale, et al., 1981, J. Immunol. 128 1963-65.) as a function of time. As controls, the conjugate was incubated with sheep red blood cells alone;
10 in the presence of rat red blood cells and human complement (the monoclonal antibody used does not bind to rat red blood cells); and in the absence of both sheep red blood cells and complement (the monoclonal antibody used does not bind to rat red blood cells). FIG. 8 shows the
15 results of these experiments. A comparison of curve (a) which represents the conjugate incubated with glutaraldehyde-fixed sheep red blood cells and human complement to the control curves labeled (b), (c) and (d) clearly demonstrates the release of free AMC in the sample
20 containing the specific antibody target and human complement. Thus, curve (b) which represents the conjugate incubated with glutaraldehyde-fixed rat red blood cells and human complement, curve (c) which represents the conjugate incubated with glutaraldehyde-
25 fixed sheep red blood cells, and curve (d) which represents the conjugate alone demonstrate no release of AMC.

The invention described and claimed herein is not
30 to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the
35 invention in addition to those shown and described herein

0088695

-63-

will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.



WE CLAIM:

1. A method for preparing an antibody conjugate, comprising:

5

(a) exposing an antibody or antibody fragment directed against an antigenic site to an oxidizing agent to generate aldehyde groups in the carbohydrate moiety of the antibody or antibody fragment to form an oxidized antibody; and

10

(b) reacting the aldehyde groups of the oxidized antibody with a hydrazine, hydrazide or amine group of a compound to form an antibody conjugate having substantially the immunoreactivity and immunospecificity of the antibody or antibody fragment.

15

2. A method according to claim 1, wherein said oxidizing agent is galactose oxidase or periodate.

20

3. A method according to claim 1, wherein said antibody fragment is the Fab fragment of an IgM antibody or a half antibody molecule.

25

4. The method according to claim 1, wherein the antibody is a monoclonal antibody.

5. The method according to claim 1, wherein the compound is a soluble linker.

30

6. The method according to claim 5, where the linker is attached to a second compound.

35

7. The method according to claim 6, wherein the second compound is an insoluble support.

8. The method according to claim 1, wherein the
5 compound is an insoluble support.

9. The method according to claim 1, wherein the antibody conjugate is stabilized by exposure to an effective amount of a reducing agent.

10
10. An antibody conjugate, comprising: a compound attached through a covalent bond to a carbohydrate moiety of an antibody, said antibody conjugate substantially retaining the immunoreactivity and
15 immunospecificity of the antibody.

11. The antibody conjugate according to claim 10, wherein the covalent bond is a hydrazone, imine or enamine.

20
12. The antibody conjugate according to claim 10, wherein the compound is a soluble linker.

25
13. The antibody conjugate according to claim 12, wherein the soluble linker is attached to a second compound.

14. The antibody conjugate according to claim 13, wherein the second compound is an insoluble support.

30
15. The antibody conjugate according to claim 10, wherein the compound is an insoluble support.

16. A method for testing for antigen,
35 comprising: mixing an antibody conjugate of claim 10 with

a sample containing antigen, and detecting the interaction of said antibody conjugate and antigen.

17. The method according to claim 16, wherein
5 the compound of the antibody conjugate is an enzyme, a radioactive compound or a fluorescent, chemiluminescent or potentially fluorescent or chemiluminescent compound.

18. A method for separating a compound from a
10 sample, comprising: contacting a sample containing a compound with an antibody conjugate of claim 10, said antibody conjugate having affinity for said compound, to form an antibody conjugate-compound complex, and separating the antibody conjugate-compound complex from
15 the sample.

19. The method according to claim 18, further comprising dissociating the antibody conjugate-compound complex to obtain purified compound.

20

20. A method for separating a cell from a sample, comprising: contacting a sample containing a cell with an antibody conjugate of claim 10, said antibody conjugate having affinity for said cell, to form an
25 antibody conjugate-cell complex, and separating the antibody conjugate-cell complex from the sample.


21. The method according to claim 20, further comprising dissociating the antibody-cell complex to
30 obtain a purified cell.

22. A method for preparing a modified antibody, comprising:


35

(a) exposing an antibody or antibody fragment directed against an antigenic site to an oxidizing agent to generate aldehyde groups in the carbohydrate moiety of the antibody or antibody fragment to form an oxidized antibody; and

(b) reacting the aldehyde groups of the oxidized antibody with a hydrazine or hydrazide derivative of a peptide linker, an amino acid linker or a linker of the general formula



wherein W is either



-CH₂-; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20,


to form a modified antibody which retains substantial immunoreactivity and immunospecificity.


23. A method for linking a compound to an antibody to prepare an antibody conjugate, comprising:

(a) exposing an antibody or antibody fragment directed against an antigenic site to an oxidizing agent to generate aldehyde groups in the carbohydrate moiety of the antibody or antibody fragment to form an oxidized antibody; and

(b) reacting the aldehyde groups of the oxidized antibody with a hydrazine or hydrazide derivative of a peptide linker, an amino acid linker or a linker of the general formula

5



wherein W is either -NH-CH₂- or

10

-CH₂-; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20,

15

said linker covalently attached to a therapeutic or diagnostic compound or an insoluble matrix to form an antibody conjugate which retains substantial immunoreactivity and immunospecificity,

20

24. A method for linking a compound to an antibody to prepare an antibody conjugate, comprising:


25


(a) exposing an antibody or antibody fragment directed against an antigenic site to an oxidizing agent to generate aldehyde groups in the carbohydrate moiety of the antibody or antibody fragment to form an oxidized antibody; and

30

(b) reacting the aldehyde groups of the oxidized antibody with a hydrazine or hydrazide derivative of a peptide linker, an amino acid linker or a linker of the general formula

35



wherein W is either -NH-CH₂- or

-CH₂-; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20,

to form a modified antibody; and

(c) forming a covalent attachment or chelator complex between the unbound terminus of the linker and a therapeutic or diagnostic compound or an insoluble matrix to form an antibody conjugate which retains substantial immunoreactivity and immunospecificity.

25. A method according to claim 22, 23 or 24, wherein said oxidizing agent is galactose oxidase or periodate.


26. A method according to claim 22, 23 or 24, wherein said antibody fragment is the Fab fragment of an IgM antibody or a half antibody molecule.

27. A method for preparing a modified antibody, comprising:

(a) binding an antibody or antibody fragment directed against an antigenic site to a second antibody directed against the Fab portion of the antibody or antibody fragment to form an immune complex;

(b) covalently attaching a peptide linker, an amino acid linker or a linker of the general formula

-70-



5 wherein W is either $-NH-CH_2-$ or

$-CH_2-$; Q is an amino acid, peptide, chelator or
chelator derivative; and n is an integer from 0
to 20,

10 to the unbound portion of the antibody or
antibody fragment to form a modified antibody;

15 (c) dissociating the immune complex to
release the modified antibody from the second
antibody; and


20 (d) separating the modified antibody from
the second antibody, said modified antibody
retaining substantial immunoreactivity and
immunospecificity.

28. A method for linking a compound to an
antibody to prepare an antibody conjugate, comprising:

25 (a) binding an antibody or antibody
fragment directed against an antigenic site to a
second antibody directed against the Fab portion
of the antibody or antibody fragment to form an
30 immune complex;

 (b) covalently attaching a peptide linker,
an amino acid linker or a linker of the general
formula

35



-71-

wherein W is either $-\text{NH}-\text{CH}_2-$ or
 $-\text{CH}_2-$; Q is an amino acid, peptide, chelator or
chelator derivative; and n is an integer from 0
to 20,

said linker covalently attached to a therapeutic
or diagnostic compound or an insoluble matrix to
the unbound portion of the antibody or antibody
fragment to form an antibody conjugate; and


(c) dissociating the immune complex to
release the antibody conjugate from the second
antibody; and

(d) separating the antibody conjugate from
the second antibody, said antibody conjugate
retaining substantial immunoreactivity and
immunospecificity.

29. A method for linking a compound to an
antibody to prepare an antibody conjugate, comprising:

(a) binding an antibody or antibody
fragment directed against antigenic site to a
second antibody directed against the Fab portion
of the antibody or antibody fragment to form an
immune complex;

(b) covalently attaching a peptide linker,
an amino acid linker or a linker of the general
formula



wherein W is either $-\text{NH}-\text{CH}_2-$ or

-CH₂-; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20,

5 to the unbound portion of the antibody or antibody fragment to form a modified antibody;

10 (c) forming a covalent bond between an unbound terminus of the linker and a therapeutic or diagnostic compound or an insoluble matrix to form an antibody conjugate;

15 (d) dissociating the immune complex to release the antibody conjugate from the second antibody; and

20 (e) separating the antibody conjugate from the second antibody, said antibody conjugate retaining substantial immunoreactivity and immunospecificity.

30. A method according to claim 27, 28 or 29, wherein said antibody fragment is the Fab fragment of an IgM antibody or a half antibody molecule.


25 31. A method according to claim 27, 28 or 29, wherein the second antibody is attached to an insoluble material.

30 32. A method according to claim 27, 28 or 29, wherein the linker is attached to the antibody by means of a carbodiimide reaction.

33. A method for preparing a modified antibody,
35 comprising:

(a) exposing an antibody or the (Fab')₂ fragment of an antibody to a mild reducing agent to produce an antibody or Fab' fragment having sulfhydryl groups, said antibody or Fab' fragment directed against an antigenic site; and

(b) reacting said sulfhydryl groups with an iodoalkyl derivative of a peptide linker, an amino acid linker or a linker of the general formula



wherein W is either -NH-CH₂- or -CH₂-; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20

to form a covalent linkage between said linker and said reduced antibody or Fab' fragment to form a modified antibody which retains substantial immunoreactivity and immunospecificity.


34. A method for linking a compound to an antibody to prepare an antibody conjugate, comprising:

(a) exposing an antibody or the (Fab')₂ fragment of an antibody to a mild reducing agent to produce an antibody or Fab' fragment having sulfhydryl groups, said antibody or Fab' fragment directed against an antigenic site, and

(b) reacting said sulfhydryl groups with an iodoalkyl derivative of a peptide linker, an

0088695

amino acid linker or a linker of the general formula



5

wherein W is either $-NH-CH_2-$ or $-CH_2-$; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20,

10

said linker covalently attached to a therapeutic or diagnostic compound or an insoluble matrix to form a covalent linkage between said linker and said reduced antibody or Fab' fragment to form an antibody conjugate which retains substantial immunoreactivity and immunospecificity.

15

35. A method for linking a compound to an antibody to prepare an antibody conjugate, comprising:


20

(a) exposing an antibody or the $(Fab')_2$ fragment of an antibody to a mild reducing agent to produce an antibody or Fab' fragment having sulfhydryl groups, said antibody or Fab' fragment directed against an antigenic site;

25

(b) reacting said sulfhydryl groups with an iodoalkyl derivative of a peptide linker, an amino acid linker or a linker of the general formula

30



wherein W is either $-NH-CH_2-$ or

35

$-\text{CH}_2-$; Q is an amino acid, peptide, chelator or chelator derivative; and n is an integer from 0 to 20,

5 to form a covalent linkage between said linker and said reduced antibody or Fab' fragment; and

10 (c) forming a covalent attachment or chelator complex between the unbound terminus of the linker and a therapeutic or diagnostic compound or an insoluble matrix to form an antibody conjugate which retains substantial immunoreactivity and immunospecificity.

15 36. The method of claim 22, 23, 24, 27, 28, 29, 33, 34 or 35, wherein said linker is a peptide comprising an amino acid sequence derived from the amino acid sequences of peptides that are substrates for activated complement components.

20 37. The method of claim 23, 24, 28 or 29, wherein the antibody is capable of activating serum complement when bound to antigen and the covalent bond between the linker and the compound is susceptible to
25 cleavage by activated complement, the resulting antibody conjugate retaining the ability to activate complement.

30 38. The method of claim 23, 24, 28 or 29, wherein the antibody is capable of activating serum complement when bound to antigen and the covalent bond between the linker and the compound is not susceptible to
35 cleavage by activated complement, the resulting antibody conjugate retaining the ability to activate complement.

39. The method of claim 23, 24, 28 or 29,
wherein the antibody is not capable of activating serum
complement when bound to antigen and the covalent bond
between the linker and the compound is susceptible to
5 cleavage by activated complement.

40. The method of claim 23, 24, 28 or 29,
wherein the antibody is not capable of activating serum
complement when bound to antigen and the covalent bond
10 between the linker and the compound is not susceptible to
cleavage by activated complement.

41. The method of claim 23, 24, 28 or 29,
wherein the antibody is not capable of activating serum
15 complement when bound to antigen and the covalent bond
between the linker and the compound is susceptible to
cleavage by serum proteases.

42. The method of claim 34 or 35, wherein the
20 covalent bond between the linker and the compound is
susceptible to cleavage by activated complement.

43. The method of claim 34 or 35, wherein the
covalent bond between the linker and the compound is not
25 susceptible to cleavage by activated complement.

44. The method of claim 34 or 35, wherein the
covalent bond between the linker and the compound is
susceptible to cleavage by serum proteases.

30

45. The method of claim 22, 23, 24, 27, 28, 29,
33, 34 or 35, wherein the antibody is a monoclonal
antibody.

35

46. The modified antibody produced according to the method of claim 22, 27 or 33.

5 47. The antibody conjugate produced according to the method of claim 23, 24, 28, 29, 34, 35, 37, 38, 39, 40, 41, 42, 43 or 44.

48. A method according to claim 37, 39 or 42, wherein the compound is an antibacterial agent.

49. A method according to claim 37, 39 or 42, wherein the compound is an antiviral agent.

10 50. A method according to claim 37, 39 or 42, wherein the compound is an antitumor agent.

51. A method according to claim 37, 39 or 42, wherein the compound is an antifungal agent.

15 52. A method according to claim 37, 39 or 42, wherein the compound is an antiparasitic agent.

53. A method according to claim 37, 39 or 42, wherein the compound is an antimycoplasmal agent.

54. A method according to claim 37, 39 or 42, wherein the compound is a cytotoxic agent.

20 55. The method of claim 38, 40 or 43, wherein the compound is a radiopharmaceutical, heavy metal, toxin or toxin fragment.

25 56. The method of claim 41 or 44, wherein the compound is a neurotransmitter, hormone, enzyme or DNA sequence.

57. A method for detecting an antigen,
comprising :

- 5 (a) contacting a material suspended of
containing said antigen with an antibody conjugate
produced according to the method of claim 37 and fluid
containing complement ; and
(b) detecting the compound released from
said antibody conjugate by action of complement.

10 58. The method of claim 57, wherein the
compound is fluorogenic.

59. The method according to claim 57, wherein
said compound is 7-amino-4-méthyl-coumarin (AMC).

60. A method according to claim 57, wherein
the linker is the tripeptide gly-gly-arg.

FIG. 1a

1/8




FIG. 1b




FIG. 2





FIG. 3

3/8



4/8







FIG. 5




5698800

FIG. 6



718

FIG. 7



8/8

FIG. 8

